SHEEL BIOTECH LIMITED (SHEEL): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1YAll

₹61 latest close · +38.6% over the last 90 sessions

₹61 month-end · −22.5% over 12 months

₹61 month-end · −23.8% since Oct '25

52-week range ₹37.80 to ₹95.55 · 1-year volatility 61.8%

Was the rally earned?

-23%share price, 1 yearEarnings-driven

Mostly earnings.

Per-share earnings took off 19 points, while the multiple moved less (P/E 10.9x to 10.6x).
The share count rose 33%.

Net profit growth+6 ptsNet profit rose about 7%, which lifts the price.

P/E change-3 ptsThe P/E fell from 10.9x to 10.6x, which lowers the price.

Share count change-25 ptsShare count rose 33%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Not shown for 3 years and 5 years: earnings were negative at one end, or there is not enough history.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare with other companies

How rough has the ride been?

Maximum drawdown-59.2%not yet recovered

1-year volatility61.8%annualised

Drawdown from peak

Largest drawdowns

-59.2% (2025-10 peak to 2026-04 low, not yet recovered)

What is the price implying?

~11%annual earnings growth implied by the price

At a P/E of 14.7x, the price would imply about 10.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹61.00
P/E: 10.6x
ROCE: 13.0%
Market Cap: ₹124 cr
Revenue (TTM): ₹110 cr
P/S: 1.1x
P/B: 1.0x
ROE: 9.2%
Debt / Equity: 0.1x
Promoter Holding: 72.3%
12M Momentum: -22.5%

52-week range

₹37.80₹95.55

40% of the way from its 52-week low to its high

Price risk

1Y volatility

61.8%

Balance sheet & cash

Interest cover

operating profit ÷ interest

8.0x

Cash from profit, 3Y

operating cash flow ÷ net profit

-0.30x

low

Share count, 1Y

+33.3%

Are profits backed by cash?

2 of 4checks within range1 beyond a threshold

Other income reliance7%Within range

Other income as a share of pre-tax profit (trailing twelve months): 7.1%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate—Not enough data

Not enough reported data to compute this.

Cash conversion-0.30xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -0.30x (cash from operations ₹-10 cr, net profit ₹33 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history—Not enough data

Not enough reported data to compute this.

Capital work in progress33% of fixed assetsWithin range

Capital work-in-progress is 33% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

What happened next to similar setups

+17.8%typical 12-month return vs the marketAbove the base rate

We found 50 past situations where a non-financial company looked like SHEEL BIOTECH LIMITED today on valuation, return on capital, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −19% to +45% vs the market, against −1% for all non-financial companies in the same months.
The analogs' median sat above that base rate (gap +18.8%, 80% range +2.7% to +25.3%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 5 beyond the range shown, drawn at the edge

Similar setups' median

+17.8%

All companies' median

−1.0%

Beat the market

64% vs 49%

50 past situations · 50 companies · 38 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ALPA Health Technology	Jan 2023	10x	9%	−27%	−31%	+13%
ALMONDZ Finance	May 2020	4x	7%	−45%	−57%	+116%
MINDTECK Technology Services	Feb 2023	9x	12%	−15%	−35%	+30%
WEIZMANIND Process Industries	Jul 2024	22x	16%	+31%	−21%	+2%
BAWEJA Consumer Services	Jul 2025	15x	—	−30%	−30%	−60%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
IFBAGRO Consumer Non-Durables	Feb 2020	9x	10%	−28%	−43%	+4%
MADHAV Non-Energy Minerals	Feb 2020	6x	—	−32%	−37%	+43%
PALASHSECU Consumer Non-Durables	Feb 2020	5x	4%	−33%	−43%	+22%

How reliable is this?

Matched on P/E, P/S, ROCE, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: P/E, 12-month momentum and drawdown from 12-month high. Not used (unavailable for this company): operating margin. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to SHEEL BIOTECH LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

3 events since Apr '26

2026
OctSharesShare count is up 33.3% over 12 months.
JunDividendDividend payout cut from 14% to 0% of profit.
AprPriceFell 59% from the Oct 2025 peak to the Apr 2026 low.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history14 months · 2025-10 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	10.6x	₹110 cr	9.2%	13.0%	0.1x
2026-10	9.8x	₹110 cr	9.4%	13.0%	0.1x
2026-09	10.4x	₹110 cr	9.4%	13.0%	0.1x
2026-08	10.7x	₹110 cr	9.4%	13.0%	0.1x
2026-07	11.8x	₹110 cr	9.4%	13.0%	0.1x
2026-06	12.1x	₹110 cr	9.4%	13.0%	0.1x
2026-05	6.0x	₹102 cr	13.1%	14.0%	0.2x
2026-04	6.5x	₹102 cr	13.1%	14.0%	0.2x
2026-03	5.6x	₹102 cr	13.1%	14.0%	0.2x
2026-02	8.3x	₹102 cr	13.1%	14.0%	0.2x
2026-01	9.2x	₹102 cr	13.1%	14.0%	0.2x
2025-12	9.9x	₹102 cr	13.1%	14.0%	0.2x
2025-11	10.9x	₹102 cr	13.1%	14.0%	0.2x
2025-10	11.1x	₹102 cr	13.1%	14.0%	0.2x

Methodology and data notes